Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03044600 · ClinicalTrials.gov registry record
Gene Expression in Hyperparathyroidism
A clinical trial, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- 22
- Enrollment target
NCT03044600: Clinical Trial study, sponsored by M.D. Anderson Cancer Center.
NCT03044600 is a clinical trial that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 22 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03044600 was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- 22 participants
- Enrollment target
Study Summary
Objectives: 1. To better define the differences in molecular genetics of parathyroid tumors in patients with MEN1, single gland parathyroid disease in patients less than 50 years old and single gland disease in patients greater than 50 years old. 2. To better define the incidence of HRPT2 mutation in young patients with primary hyperparathyroidism and determine whether routine testing in these patients is indicated.
Interventions
- OTHER Chart Review
- OTHER HRPT2 Mutation Evaluation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2012-11-07 |
| Est. Completion | 2017-10-18 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03044600
The ClinicalTrials.gov registry entry for NCT03044600 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Chart Review is the first listed.
NCT03044600 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03044600 about?
NCT03044600 is a clinical study titled "Gene Expression in Hyperparathyroidism". Objectives: 1. To better define the differences in molecular genetics of parathyroid tumors in patients with MEN1, single gland parathyroid disease in patients less than 50 years old and single gland disease in patients greater than 50 years old. 2. To better define the incidence of HRPT2 mutation ...
What is the current status of trial NCT03044600?
This trial is currently terminated. The enrollment target is 22 participants. The study started on 2012-11-07. Estimated completion is 2017-10-18.
What interventions are being tested in trial NCT03044600?
The interventions under investigation include: Chart Review (OTHER), HRPT2 Mutation Evaluation (OTHER).
Who is sponsoring clinical trial NCT03044600?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.